Abstract
Background Non-alcoholic fatty liver disease (NAFLD) is a common liver disease. The aim of the present study was to explore the relation of visfatin with underlying histopathological changes of NAFLD patients. Subjects A population of 55 NAFLD patients was analyzed in a cross-sectional study. A liver biopsy was realized. Weight, basal glucose, insulin, insulin resistance (HOMA), total cholesterol, LDL cholesterol, HDL cholesterol, triglycerides, and visfatin levels were measured. A bioimpedance was performed. Results and conclusions The mean age was 42.8 ± 11.2 years, the mean BMI was 33.1 ± 10.2 with 37 males (67.3%) and 18 females (32.7%). Probabilities to have; portal inflammation increased 1.11 (CI95%:1.03–1.50) with each increment of 1 ng/ml of visfatin concentration, high grade of steatosis increased 1.25 (CI 95%:1.06–1.61) with each unit of insulin concentrations, fibrosis increased 1.12 (CI 95%:1.02–1.43) with each unit of fat mass and lobulillar inflammation increased 13.4 (CI 95%:1.3–147) with each unit of HOMA-IR. Portal inflammation frequencies were different between groups (low visfatin group 13.07 < ng/ml: 37.5% versus high visfatin group 13.07 > ng/ml: 62.5%; P < 0.05). In conclusion, several histopathological changes in liver biopsies could be explained by insulin concentrations, HOMA-IR, and fat mass amount. Moreover, visfatin plasma concentrations could predict the presence of portal inflammation in NAFLD patients.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Meier U, Gressner AM. Endocrine regulation of energy metabolism: review of pathobiochemical and clinical chemical aspects of leptin, ghrelin, adiponectin and resistin. Clin Chem. 2004;50:1511–1525. doi:10.1373/clinchem.2004.032482.
Fukuhara A, Matsuda M, Nishizawa M, et al. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science. 2005;307:426–430. doi:10.1126/science.1097243.
Ognjanovic S. Genomic organization of the gene coding for human pre-B-cell colony enhancing factor and expression in human fetal membranes. J Mol Endocrinol. 2001;26:107–117. doi:10.1677/jme.0.0260107.
Ludwig J, Viggiano TR, McGill DB. Oh BJ: Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc. 1980;55:434–438.
American Diabetes Association. Standards of medical care in diabetes 2007. Diabetes Care. 2008;30:s4–s41. doi:10.2337/dc07-S004.
Mathews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF. Homeostasis model assessment: Insulin resistance and beta cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412–414. doi:10.1007/BF00280883.
Pichard C, Slosman D, Hirschel B, Kyle U. Bioimpedance analysis in patients: an improved method for nutritional follow-up. Clin Res. 1993;41:53.
Brunt EM. Nonalcoholic steatohepatitis: definition and pathology. Semin Liver Dis. 2001;21:3–16. doi:10.1055/s-2001-12925.
Bondini S, Kleiner DE, Goodman ZD, Gramlich T, Younossi ZM. Pathologic assessment of non-alcoholic fatty liver disease. Clin Liver Dis. 2007;11:17–23. doi:10.1016/j.cld.2007.02.002.
Venturi C, Zoppini G, Zamboni C, Muggeo M. Insulin sensitivity and hepatic steatosis in obese subjects with normal glucose tolerance. Nutr Metab Cardiovasc Dis. 2004;14:200–204. doi:10.1016/S0939-4753(04)80005-X.
Browning JD, Horton JD. Molecular mediators of hepatic steatosis and liver injury. J Clin Invest. 2004;114:147–152.
Brendt J, Klöting N, Kralisch S, et al. Plasma visfatin concentrations and fat depot specific RNA expression in humans. Diabetes. 2005;54:2911–2916. doi:10.2337/diabetes.54.10.2911.
Senthi JK, Vidal Puig A. Visfatin: the missing link between intra-abdominal obesity and diabetes? Trends Mol Med. 2005;11:344–350. doi:10.1016/j.molmed.2005.06.010.
Dogru T, Sonmez A, Tasci I, et al. Plasma visfatin levels in patients with newly diagnosed and untreated type 2 diabetes mellitus and impaired glucose tolerant. Diabetes Res Clin Pract. 2006;(Sept):4. (Epub ahead of print).
Li L, Yang G, Li Q, et al. Changes and relations of circulating visfatin, apelin, and resistin levels in normal, impaired glucose tolerance, and type 2 diabetic subjects. Exp Clin Endocrinol Diabetes. 2006;114:544–548. doi:10.1055/s-2006-948309.
El-Assal O, Hong F, Kim WH, Radaeva S, Gao B. IL-6 deficient mice are susceptible to ethanol-induced hepatic steatosis: IL6 protects against ethanol induced stress and mitochondrial permeability. Cell Mol Immunol. 2004;1:205–211.
Teoh N, Field J, Farrel G. IL-6 is a key mediator of the hepatoprotective and pro-proliferative effects of ischemic preconditioning mice. J Hepatol. 2006;45:20–27. doi:10.1016/j.jhep.2006.01.039.
Retnakaran R, Youn BS, Liu Y, et al. Correlation of circulating full-length visfatin (PBEF/Nampt) with metabolic parameters in subjects with and without diabetes: A cross-sectional study. Clin Endocrinol (Oxf). 2008; Epub ahead of print. oxf.
de Luis DA, Aller R, Izaola O, Conde R, Gonzalez M, Romero E. Effect of a hypocaloric diet on circulating visfatin in obese non diabetic patients. Nutrition. 2008;24:517–521.
Pfützner A, Hanefeld M, Lübben G, et al. Visfatin: Aputative biomarker for metabolic syndrome is not influenced by pioglitazone or simvastatin treatment in nondiabetic patients at cardiovascular risk-results from PIOSTAR study. Horm Metab Res. 2007;39:764–768. doi:10.1055/s-2007-985867.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Aller, R., de Luis, D.A., Izaola, O. et al. Influence of Visfatin on Histopathological Changes of Non-alcoholic Fatty Liver Disease. Dig Dis Sci 54, 1772–1777 (2009). https://doi.org/10.1007/s10620-008-0539-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10620-008-0539-9